Search Results - "Wolf, Denise"

Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity by Broz, Miranda L., Binnewies, Mikhail, Boldajipour, Bijan, Nelson, Amanda E., Pollack, Joshua L., Erle, David J., Barczak, Andrea, Rosenblum, Michael D., Daud, Adil, Barber, Diane L., Amigorena, Sebastian, van’t Veer, Laura J., Sperling, Anne I., Wolf, Denise M., Krummel, Matthew F.

“…It is well understood that antigen-presenting cells (APCs) within tumors typically do not maintain cytotoxic T cell (CTL) function, despite engaging them…”
Get full text

Critical Role for CD103+/CD141+ Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma by Roberts, Edward W., Broz, Miranda L., Binnewies, Mikhail, Headley, Mark B., Nelson, Amanda E., Wolf, Denise M., Kaisho, Tsuneyasu, Bogunovic, Dusan, Bhardwaj, Nina, Krummel, Matthew F.

“…Intratumoral dendritic cells (DC) bearing CD103 in mice or CD141 in humans drive intratumoral CD8+ T cell activation. Using multiple strategies, we identified…”
Get full text

A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments by Barry, Kevin C., Hsu, Joy, Broz, Miranda L., Cueto, Francisco J., Binnewies, Mikhail, Combes, Alexis J., Nelson, Amanda E., Loo, Kimberly, Kumar, Raj, Rosenblum, Michael D., Alvarado, Michael D., Wolf, Denise M., Bogunovic, Dusan, Bhardwaj, Nina, Daud, Adil I., Ha, Patrick K., Ryan, William R., Pollack, Joshua L., Samad, Bushra, Asthana, Saurabh, Chan, Vincent, Krummel, Matthew F.

“…Intratumoral stimulatory dendritic cells (SDCs) play an important role in stimulating cytotoxic T cells and driving immune responses against cancer…”
Get full text

Gene co-expression modules as clinically relevant hallmarks of breast cancer diversity by Wolf, Denise M, Lenburg, Marc E, Yau, Christina, Boudreau, Aaron, van 't Veer, Laura J

“…Co-expression modules are groups of genes with highly correlated expression patterns. In cancer, differences in module activity potentially represent the…”
Get full text

Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity by Broz, Miranda L., Binnewies, Mikhail, Boldajipour, Bijan, Nelson, Amanda E., Pollack, Joshua L., Erle, David J., Barczak, Andrea, Rosenblum, Michael D., Daud, Adil, Barber, Diane L., Amigorena, Sebastian, van’t Veer, Laura J., Sperling, Anne I., Wolf, Denise M., Krummel, Matthew F.

Get full text

Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies by Wolf, Denise M., Yau, Christina, Wulfkuhle, Julia, Brown-Swigart, Lamorna, Gallagher, Rosa I., Lee, Pei Rong Evelyn, Zhu, Zelos, Magbanua, Mark J., Sayaman, Rosalyn, O’Grady, Nicholas, Basu, Amrita, Delson, Amy, Coppé, Jean Philippe, Lu, Ruixiao, Braun, Jerome, Asare, Smita M., Sit, Laura, Matthews, Jeffrey B., Perlmutter, Jane, Hylton, Nola, Liu, Minetta C., Pohlmann, Paula, Symmans, W. Fraser, Rugo, Hope S., Isaacs, Claudine, DeMichele, Angela M., Yee, Douglas, Berry, Donald A., Pusztai, Lajos, Petricoin, Emanuel F., Hirst, Gillian L., Esserman, Laura J., van 't Veer, Laura J.

“…Using pre-treatment gene expression, protein/phosphoprotein, and clinical data from the I-SPY2 neoadjuvant platform trial (NCT01042379), we create alternative…”
Get full text

Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin by Hoadley, Katherine A., Yau, Christina, Wolf, Denise M., Cherniack, Andrew D., Tamborero, David, Ng, Sam, Leiserson, Max D.M., Niu, Beifang, McLellan, Michael D., Uzunangelov, Vladislav, Zhang, Jiashan, Kandoth, Cyriac, Akbani, Rehan, Shen, Hui, Omberg, Larsson, Chu, Andy, Margolin, Adam A., van’t Veer, Laura J., Lopez-Bigas, Nuria, Laird, Peter W., Raphael, Benjamin J., Ding, Li, Robertson, A. Gordon, Byers, Lauren A., Mills, Gordon B., Weinstein, John N., Van Waes, Carter, Chen, Zhong, Collisson, Eric A., Benz, Christopher C., Perou, Charles M., Stuart, Joshua M.

“…Recent genomic analyses of pathologically defined tumor types identify “within-a-tissue” disease subtypes. However, the extent to which genomic signatures are…”
Get full text

Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial by Pusztai, Lajos, Yau, Christina, Wolf, Denise M., Han, Hyo S., Du, Lili, Wallace, Anne M., String-Reasor, Erica, Boughey, Judy C., Chien, A. Jo, Elias, Anthony D., Beckwith, Heather, Nanda, Rita, Albain, Kathy S., Clark, Amy S., Kemmer, Kathleen, Kalinsky, Kevin, Isaacs, Claudine, Thomas, Alexandra, Shatsky, Rebecca, Helsten, Theresa L., Forero-Torres, Andres, Liu, Minetta C., Brown-Swigart, Lamorna, Petricoin, Emmanuel F., Wulfkuhle, Julia D., Asare, Smita M., Wilson, Amy, Singhrao, Ruby, Sit, Laura, Hirst, Gillian L., Berry, Scott, Sanil, Ashish, Asare, Adam L., Matthews, Jeffrey B., Perlmutter, Jane, Melisko, Michelle, Rugo, Hope S., Schwab, Richard B., Symmans, W. Fraser, Yee, Doug, van’t Veer, Laura J., Hylton, Nola M., DeMichele, Angela M., Berry, Donald A., Esserman, Laura J.

“…The combination of PD-L1 inhibitor durvalumab and PARP inhibitor olaparib added to standard paclitaxel neoadjuvant chemotherapy (durvalumab/olaparib/paclitaxel…”
Get full text

Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis by Bidard, François-Clément, Michiels, Stefan, Riethdorf, Sabine, Mueller, Volkmar, Esserman, Laura J, Lucci, Anthony, Naume, Bjørn, Horiguchi, Jun, Gisbert-Criado, Rafael, Sleijfer, Stefan, Toi, Masakazu, Garcia-Saenz, Jose A, Hartkopf, Andreas, Generali, Daniele, Rothé, Françoise, Smerage, Jeffrey, Muinelo-Romay, Laura, Stebbing, Justin, Viens, Patrice, Magbanua, Mark Jesus M, Hall, Carolyn S, Engebraaten, Olav, Takata, Daisuke, Vidal-Martínez, José, Onstenk, Wendy, Fujisawa, Noriyoshi, Diaz-Rubio, Eduardo, Taran, Florin-Andrei, Cappelletti, Maria Rosa, Ignatiadis, Michail, Proudhon, Charlotte, Wolf, Denise M, Bauldry, Jessica B, Borgen, Elin, Nagaoka, Rin, Carañana, Vicente, Kraan, Jaco, Maestro, Marisa, Brucker, Sara Yvonne, Weber, Karsten, Reyal, Fabien, Amara, Dominic, Karhade, Mandar G, Mathiesen, Randi R, Tokiniwa, Hideaki, Llombart-Cussac, Antonio, Meddis, Alessandra, Blanche, Paul, d'Hollander, Koenraad, Cottu, Paul, Park, John W, Loibl, Sibylle, Latouche, Aurélien, Pierga, Jean-Yves, Pantel, Klaus

“…Abstract Background We conducted a meta-analysis in nonmetastatic breast cancer patients treated by neoadjuvant chemotherapy (NCT) to assess the clinical…”
Get full text

Subtype and pathway specific responses to anticancer compounds in breast cancer by Heiser, Laura M, Sadanandam, Anguraj, Kuo, Wen-Lin, Benz, Stephen C, Goldstein, Theodore C, Ng, Sam, Gibb, William J, Wang, Nicholas J, Ziyad, Safiyyah, Tong, Frances, Bayani, Nora, Hu, Zhi, Billig, Jessica I, Dueregger, Andrea, Lewis, Sophia, Jakkula, Lakshmi, Korkola, James E, Durinck, Steffen, Pepin, François, Guan, Yinghui, Purdom, Elizabeth, Neuvial, Pierre, Bengtsson, Henrik, Wood, Kenneth W, Smith, Peter G, Vassilev, Lyubomir T, Hennessy, Bryan T, Greshock, Joel, Bachman, Kurtis E, Hardwicke, Mary Ann, Park, John W, Marton, Laurence J, Wolf, Denise M, Collisson, Eric A, Neve, Richard M, Mills, Gordon B, Speed, Terence P, Feiler, Heidi S, Wooster, Richard F, Haussler, David, Stuart, Joshua M, Gray, Joe W, Spellman, Paul T

“…Breast cancers are comprised of molecularly distinct subtypes that may respond differently to pathway-targeted therapies now under development. Collections of…”
Get full text

Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy by Magbanua, Mark Jesus M., Brown Swigart, Lamorna, Ahmed, Ziad, Sayaman, Rosalyn W., Renner, Derrick, Kalashnikova, Ekaterina, Hirst, Gillian L., Yau, Christina, Wolf, Denise M., Li, Wen, Delson, Amy L., Asare, Smita, Liu, Minetta C., Albain, Kathy, Chien, A. Jo, Forero-Torres, Andres, Isaacs, Claudine, Nanda, Rita, Tripathy, Debu, Rodriguez, Angel, Sethi, Himanshu, Aleshin, Alexey, Rabinowitz, Matthew, Perlmutter, Jane, Symmans, W. Fraser, Yee, Douglas, Hylton, Nola M., Esserman, Laura J., DeMichele, Angela M., Rugo, Hope S., van ’t Veer, Laura J.

“…Circulating tumor DNA (ctDNA) analysis may improve early-stage breast cancer treatment via non-invasive tumor burden assessment. To investigate…”
Get full text

ENPP1 is an innate immune checkpoint of the anticancer cGAMP-STING pathway in breast cancer by Wang, Songnan, Böhnert, Volker, Joseph, Alby J, Sudaryo, Valentino, Skariah, Gemini, Swinderman, Jason T, Yu, Feiqiao B, Subramanyam, Vishvak, Wolf, Denise M, Lyu, Xuchao, Gilbert, Luke A, Van't Veer, Laura J, Goodarzi, Hani, Li, Lingyin

“…Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) expression correlates with poor prognosis in many cancers, and we previously discovered that ENPP1…”
Get full text

Memory in microbes: quantifying history-dependent behavior in a bacterium by Wolf, Denise M, Fontaine-Bodin, Lisa, Bischofs, Ilka, Price, Gavin, Keasling, Jay, Arkin, Adam P

“…Memory is usually associated with higher organisms rather than bacteria. However, evidence is mounting that many regulatory networks within bacteria are…”
Get full text

Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer by Blenman, Kim R M, Marczyk, Michal, Karn, Thomas, Qing, Tao, Li, Xiaotong, Gunasekharan, Vignesh, Yaghoobi, Vesal, Bai, Yalai, Ibrahim, Eiman Y, Park, Tristen, Silber, Andrea, Wolf, Denise M, Reisenbichler, Emily, Denkert, Carsten, Sinn, Bruno V, Rozenblit, Mariya, Foldi, Julia, Rimm, David L, Loibl, Sibylle, Pusztai, Lajos

“…We examined gene expression, germline variant, and somatic mutation features associated with pathologic response to neoadjuvant durvalumab plus chemotherapy in…”
Get full text

The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting by Severson, Tesa M, Wolf, Denise M, Yau, Christina, Peeters, Justine, Wehkam, Diederik, Schouten, Philip C, Chin, Suet-Feung, Majewski, Ian J, Michaut, Magali, Bosma, Astrid, Pereira, Bernard, Bismeijer, Tycho, Wessels, Lodewyk, Caldas, Carlos, Bernards, René, Simon, Iris M, Glas, Annuska M, Linn, Sabine, van 't Veer, Laura

“…Patients with BRCA1-like tumors correlate with improved response to DNA double-strand break-inducing therapy. A gene expression-based classifier was developed…”
Get full text

Toward developing a metastatic breast cancer treatment strategy that incorporates history of response to previous treatments by Olow, Aleksandra K, Veer, Laura van 't, Wolf, Denise M

“…Information regarding response to past treatments may provide clues concerning the classes of drugs most or least likely to work for a particular metastatic or…”
Get full text

Control, exploitation and tolerance of intracellular noise by Rao, Christopher V, Wolf, Denise M, Arkin, Adam P

“…Noise has many roles in biological function, including generation of errors in DNA replication leading to mutation and evolution, noise-driven divergence of…”
Get full text

Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial by Clark, Amy S., Yau, Christina, Wolf, Denise M., Petricoin, Emanuel F., van ‘t Veer, Laura J., Yee, Douglas, Moulder, Stacy L., Wallace, Anne M., Chien, A. Jo, Isaacs, Claudine, Boughey, Judy C., Albain, Kathy S., Kemmer, Kathleen, Haley, Barbara B., Han, Hyo S., Forero-Torres, Andres, Elias, Anthony, Lang, Julie E., Ellis, Erin D., Yung, Rachel, Tripathy, Debu, Nanda, Rita, Wulfkuhle, Julia D., Brown-Swigart, Lamorna, Gallagher, Rosa I., Helsten, Teresa, Roesch, Erin, Ewing, Cheryl A., Alvarado, Michael, Crane, Erin P., Buxton, Meredith, Clennell, Julia L., Paoloni, Melissa, Asare, Smita M., Wilson, Amy, Hirst, Gillian L., Singhrao, Ruby, Steeg, Katherine, Asare, Adam, Matthews, Jeffrey B., Berry, Scott, Sanil, Ashish, Melisko, Michelle, Perlmutter, Jane, Rugo, Hope S., Schwab, Richard B., Symmans, W. Fraser, Hylton, Nola M., Berry, Donald A., Esserman, Laura J., DeMichele, Angela M.

“…HER2-targeted therapy dramatically improves outcomes in early breast cancer. Here we report the results of two HER2-targeted combinations in the neoadjuvant…”
Get full text

B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer by Steenbruggen, Tessa G, Wolf, Denise M, Campbell, Michael J, Sanders, Joyce, Cornelissen, Sten, Thijssen, Bram, Salgado, Roberto A, Yau, Christina, O-Grady, Nick, Basu, Amrita, Bhaskaran, Rajith, Mittempergher, Lorenza, Hirst, Gillian L, Coppe, Jean-Philippe, Kok, Marleen, Sonke, Gabe S, van 't Veer, Laura J, Horlings, Hugo M

“…Abstract Background Despite major improvements in treatment of HER2-positive metastatic breast cancer (MBC), only few patients achieve complete remission and…”
Get full text

Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial by Parker, Barbara A., Shatsky, Rebecca A., Schwab, Richard B., Wallace, Anne M., Wolf, Denise M., Hirst, Gillian L., Brown-Swigart, Lamorna, Esserman, Laura J., van ’t Veer, Laura J., Ghia, Emanuela M., Yau, Christina, Kipps, Thomas J.

“…Purpose ROR1 and ROR2 are Type 1 tyrosine kinase-like orphan receptors for Wnt5a that are associated with breast cancer progression. Experimental agents…”
Get full text